Catalog No. Size PriceQuantity
M7972-2 2mg solid $225
M7972-10 10mg solid $830


(R)-MG132 is a potent, reversible, and cell permeable proteasome inhibitor.

Product information

CAS Number: 1211877-36-9

Molecular Weight: 489.65

Formula: C27H43N3O5



(S, R, S)-(-)-MG-132

Chemical Name: N-[(phenylmethoxy)carbonyl]-L-leucyl-N-[(1R)-1-formyl-3-methylbutyl]-L-leucinamide

Smiles: CC(C)C[C@H](NC(=O)OCC1C=CC=CC=1)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CC=O)CC(C)C


InChi: InChI=1S/C27H43N3O5/c1-18(2)14-22(12-13-31)28-25(32)23(15-19(3)4)29-26(33)24(16-20(5)6)30-27(34)35-17-21-10-8-7-9-11-21/h7-11,13,18-20,22-24H,12,14-17H2,1-6H3,(H,28,32)(H,29,33)(H,30,34)/t22-,23-,24+/m1/s1

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO: 90 mg/mL(189.22 mM). Water: Insoluble.

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥360 days if stored properly.

Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

(R)-MG-132, the stereoisomer of MG-132, is studied as a potential inhibitor of chymotrypsin-like, trypsin-like, and peptidylglutamyl peptide hydrolyzing activities of proteasome[1]. MG-132 and (R)-MG-132 are investigated for inhibition of ChTL, trypsin-like (TL) and peptidylglutamyl peptide hydrolyzing (PGPH) activities of purified 20S proteasomes isolated from human erythrocytes. For MG-132, the IC50s of 0.89 μM, 104.43 μM, and 5.7 μM for ChTL, TL, and PGPH, respectively. For (R)-MG-132, the IC50s of 0.22 μM, 34.4 μM, and 2.95 μM for ChTL, TL, and PGPH, respectively[1].

In Vivo:

Administration of (R)-MG-132 effectively rescues the expression levels and plasma membrane localization of dystrophin, β-dystroglycan, α-bdystroglycan, and α-sarcoglycan in skeletal muscle fibers from mdx mice, reduces muscle membrane damage, and ameliorates the histopathological signs of muscular dystrophy. (R)-MG-132 treatment significantly reduces immobilization-induced skeletal muscle atrophy in mice, by downregulating the muscle-specific ubiquitin ligases atrogin-1/MAFbx and MuRF-1 mRNA.


  1. Mroczkiewicz M, et al. Studies of the synthesis of all stereoisomers of MG-132 proteasome inhibitors in the tumor targeting approach. J Med Chem. 2010 Feb 25;53(4):1509-18.
  2. Tsubuki S, et al. J Biochem, 1996, 119(3), 572-576.
  3. Crawford LJ, et al. Cancer Res, 2006, 66(12), 6379-6386.
  4. Bonuccelli G, et al. Am J Pathol, 2003, 163(4), 1663-1675.
  5. Li W, et al. Cancer Res, 2007, 67(5), 2247-2255.
  6. Caron AZ, et al. BMC Musculoskelet Disord, 2011, 12:185.
  7. Fiedler MA, et al. Am J Respir Cell Mol Biol, 1998, 19(2), 259-68.
  8. MacLaren AP, et al. Cell Death Differ, 2001, 8(3), 210-218.
  9. Diallo JS, et al. Br J Cancer, 2008, 99(10), 1613-1622.
  10. Harhouri K, et al. EMBO Mol Med. 2017, 9(9):1294-1313.

Products are for research use only. Not for human use.

Payment & Security

PayPal Venmo

Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.

Estimate shipping

You may also like

Recently viewed